Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis
Copyright © 2023. Published by Elsevier B.V..
Mastocytosis is a heterogeneous disease associated to uncontrolled proliferation and increased density of mast cells in different organs. This clonal disorder is related to gain-of-function pathogenic variants of the c-kit gene that encodes for KIT (CD117) expressed on mast cell membrane. Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine, which plays a key role in allergic disorders and several cancers. TSLP is a survival and activating factor for human mast cells through the engagement of the TSLP receptor. Activated human mast cells release several preformed mediators, including tryptase. Increased mast cell-derived tryptase is a diagnostic biomarker of mastocytosis. In this study, we found that in these patients serum concentrations of TSLP were lower than healthy donors. There was an inverse correlation between TSLP and tryptase concentrations in mastocytosis. Incubation of human recombinant TSLP with sera from patients with mastocytosis, containing increasing concentrations of tryptase, concentration-dependently decreased TSLP immunoreactivity. Similarly, recombinant β-tryptase reduced the immunoreactivity of recombinant TSLP, inducing the formation of a cleavage product of approximately 10 kDa. Collectively, these results indicate that TSLP is a substrate for human mast cell tryptase and highlight a novel loop involving these mediators in mastocytosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
European journal of internal medicine - 117(2023) vom: 08. Nov., Seite 111-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marcella, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytokines |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 28.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejim.2023.07.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36000282X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36000282X | ||
| 003 | DE-627 | ||
| 005 | 20231229124124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejim.2023.07.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM36000282X | ||
| 035 | |a (NLM)37500310 | ||
| 035 | |a (PII)S0953-6205(23)00257-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marcella, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 28.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Mastocytosis is a heterogeneous disease associated to uncontrolled proliferation and increased density of mast cells in different organs. This clonal disorder is related to gain-of-function pathogenic variants of the c-kit gene that encodes for KIT (CD117) expressed on mast cell membrane. Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine, which plays a key role in allergic disorders and several cancers. TSLP is a survival and activating factor for human mast cells through the engagement of the TSLP receptor. Activated human mast cells release several preformed mediators, including tryptase. Increased mast cell-derived tryptase is a diagnostic biomarker of mastocytosis. In this study, we found that in these patients serum concentrations of TSLP were lower than healthy donors. There was an inverse correlation between TSLP and tryptase concentrations in mastocytosis. Incubation of human recombinant TSLP with sera from patients with mastocytosis, containing increasing concentrations of tryptase, concentration-dependently decreased TSLP immunoreactivity. Similarly, recombinant β-tryptase reduced the immunoreactivity of recombinant TSLP, inducing the formation of a cleavage product of approximately 10 kDa. Collectively, these results indicate that TSLP is a substrate for human mast cell tryptase and highlight a novel loop involving these mediators in mastocytosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mast cells | |
| 650 | 4 | |a Mastocytosis | |
| 650 | 4 | |a TSLP | |
| 650 | 4 | |a Thymic stromal lymphopoietin | |
| 650 | 4 | |a Tryptase | |
| 650 | 7 | |a Thymic Stromal Lymphopoietin |2 NLM | |
| 650 | 7 | |a GT0IL38SP4 |2 NLM | |
| 650 | 7 | |a Tryptases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.59 |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Petraroli, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Canè, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Anne Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Poto, Remo |e verfasserin |4 aut | |
| 700 | 1 | |a Parente, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Palestra, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Cristinziano, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Modestino, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Galdiero, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Marone, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Triggiani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Loffredo, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of internal medicine |d 1997 |g 117(2023) vom: 08. Nov., Seite 111-118 |w (DE-627)NLM089689097 |x 1879-0828 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2023 |g day:08 |g month:11 |g pages:111-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejim.2023.07.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2023 |b 08 |c 11 |h 111-118 | ||